Form 4 for RGNX REGENXBIO Inc.
Accepted 2026-01-08 00:00:00 ET · period of report 2026-01-06 · accession 0001346164-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-08 | 2026-01-06 | RGNX | Simpson Curran | CEO, Dir | A - Grant | $0.00 | +144.9K | 342.5K | +73% | $0 |
| D | 2026-01-08 | 2026-01-06 | RGNX | Simpson Curran | CEO, Dir | A - Grant | $0.00 | +233.7K | 233.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-06 | A | A | 144,864 | $0.00 | 342,467 | D | — | — | (F1) Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer. |
| 2 | Derivative | Stock Options (Right to buy) | 2026-01-06 | A | A | 233,651 | $0.00 | 233,651 | D | $14.18 · — to 2036-01-06 | 233,651 Common Stock | (F2) 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer. |